Alexion Pharmaceuticals Price Target Raised to $207.00 at Stifel Nicolaus (ALXN)
Investment analysts at Stifel Nicolaus lifted their price target on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $138.00 to $207.00 in a note issued to investors on Friday, AR Network reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price target indicates a potential upside of 30.41% from the company’s current price.
In other Alexion Pharmaceuticals news, EVP Stephen P. Squinto sold 1,118 shares of Alexion Pharmaceuticals stock on the open market in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $133.31, for a total transaction of $149,040.58. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 2.02% on Friday, hitting $158.73. 3,063,832 shares of the company’s stock traded hands. Alexion Pharmaceuticals has a 52 week low of $81.82 and a 52 week high of $169.98. The stock’s 50-day moving average is $134.5 and its 200-day moving average is $119.3. The company has a market cap of $31.123 billion and a price-to-earnings ratio of 91.63.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings data on Thursday, January 30th. The company reported $0.87 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million. Analysts expect that Alexion Pharmaceuticals will post $3.60 EPS for the current fiscal year.
A number of other firms have also recently commented on ALXN. Analysts at Brean Capital raised their price target on shares of Alexion Pharmaceuticals from $142.00 to $200.00 in a research note to investors on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Barclays reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note to investors on Friday, January 10th. They now have a $141.00 price target on the stock, up previously from $127.00. Finally, analysts at Nomura initiated coverage on shares of Alexion Pharmaceuticals in a research note to investors on Wednesday, January 8th. They set a “buy” rating and a $150.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Alexion Pharmaceuticals presently has an average rating of “Buy” and an average target price of $149.28.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.